Pharmaceutical intermediates
Olaparib Intermediates
5 pharmaceutical intermediates for Olaparib. Indication: Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Castration-resistant prostate cancer; Pancreatic cancer; Breast cancer; Endometrial cancer.
About Olaparib
- Originator
- Astrazeneca
- Indication
- Prostate cancer; Ovarian cancer; Fallopian tube carcinoma; Peritoneal carcinoma; Castration-resistant prostate cancer; Pancreatic cancer; Breast cancer; Endometrial cancer
- Approved Date
- 12/19/2014
- DS/DP
- 08/12/2027
Available intermediates
5 intermediates currently listed for Olaparib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Fluoro-5-formylbenzonitrile | 218301-22-5 | / | / |
| 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]benzonitrile | 763114-25-6 | / | / |
| 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin -1-yl)Methyl)benzoic acid | 763114-26-7 | / | / |
| 1-(Cyclopropylcarbonyl)piperazine hydrochloride | 1021298-67-8 | / | / |
| 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid | 61260-15-9 | / | / |
Other programs under O
Building toward Olaparib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →